LY-344545

LY-344545
Identifiers
	IUPAC name (αS)-α-Amino-α-[(1R,2R)-2-carboxycyclopropyl]-9H-xanthene-9-propanoic acid;
CAS Number	201851-20-9;
PubChem CID	10618042;
ChemSpider	8793407;
UNII	9ZSQ1C4209;
Chemical and physical data
Formula	C20H19NO5
Molar mass	353.374 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc2c(c1)C(c3ccccc3O2)C[C@]([C@@H]4C[C@H]4C(=O)O)(C(=O)O)N;
	InChI InChI=1S/C20H19NO5/c21-20(19(24)25,15-9-13(15)18(22)23)10-14-11-5-1-3-7-16(11)26-17-8-4-2-6-12(14)17/h1-8,13-15H,9-10,21H2,(H,22,23)(H,24,25)/t13-,15-,20+/m1/s1; Key:VLZBRVJVCCNPRJ-RCDCFZSISA-N;
	(verify)

LY-344,545 is a research drug developed by the pharmaceutical company Eli Lilly, which acts as an antagonist for the metabotropic glutamate receptor subtype mGluR₅. It is an epimer of another metabotropic glutamate receptor antagonist, the mGluR_2/3-selective LY-341,495.^[1]^[2]

References

^ Ornstein PL, Bleisch TJ, Arnold MB, Kennedy JH, Wright RA, Johnson BG, et al. (January 1998). "2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability". Journal of Medicinal Chemistry. 41 (3): 358–78. doi:10.1021/jm970498o. PMID 9464367.
^ Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, et al. (September 2000). "A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices". British Journal of Pharmacology. 131 (2): 239–44. doi:10.1038/sj.bjp.0703574. PMC 1572327. PMID 10991916.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.